Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta.
Apoptosis of autoaggressive T-cells in the CNS is an effective, noninflammatory mechanism for the resolution of T-cell infiltrates, contributing to clinical recovery in T-cell-mediated neuroinflammatory diseases. The clearance of apoptotic leukocytes by tissue-specific phagocytes is critical in the resolution of the inflammatory infiltrate and leads to a profound downregulation of phagocyte immune functions. Adult human microglia from surgically removed normal brain tissue was used in a standardized, light-microscopic in vitro phagocytosis assay of apoptotic autologous peripheral blood-derived mononuclear cells (MNCs). Microglia from five different patients had a high capacity for the uptake of apoptotic MNCs in contrast to nonapoptotic target cells with the phagocytosis rate for nonapoptotic MNCs amounting to only 61.6% of the apoptotic MNCs. A newly described phosphatidylserine receptor, critical in the phagocytosis of apoptotic cells by macrophages, is also expressed at similar levels on human microglia. The effects of the therapeutically used immunomodulatory agent interferon-beta (IFNbeta) were investigated using Lewis rat microglia and apoptotic, encephalitogenic, myelin basic protein-specific autologous T-cells. Also, rat microglia had a high capacity to phagocytose apoptotic T-cells specifically. IFNbeta increased the phagocytosis of apoptotic T-cells to 36.8% above the untreated controls. The enhanced phagocytic activity was selective for apoptotic T-cells and was not mediated by increased IL-10 secretion. Apoptotic inflammatory cells may be efficiently and rapidly removed by microglial cells in the autoimmune-inflamed human CNS. The in vitro increase of phagocytosis by IFNbeta merits further investigations whether this mechanism could also be therapeutically exploited.
Chan
Andrew
A
Department of Neurology, Julius-Maximilians-University, Würzburg, Germany. andrewhkchan@hotmail.com
Seguin
Rosanne
R
Magnus
Tim
T
Papadimitriou
Christina
C
Toyka
Klaus V
KV
Antel
Jack P
JP
Gold
Ralf
R
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology*; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D004660:Encephalitis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use; D016753:Interleukin-10 / Q000276:immunology; D017628:Microglia / Q000187:drug effects / Q000276:immunology*; D004676:Myelin Basic Protein / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology*; D010768:Phosphoserine / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
D016207:Cytokines; D004676:Myelin Basic Protein; D009842:Oligopeptides; D016753:Interleukin-10; D010768:Phosphoserine; D016899:Interferon-beta; C046617:arginyl-glycyl-aspartyl-serine